As EFS was considered only in patients achieved CR after induction therapies, lack of association between UGT1A1 polymorphisms and EFS observed in our study suggests other mechanisms other than chemosensitivity might also play a role in AML prognosis. This evidence concerns the gene UGT1A1 and acute myeloid leukemia.